The “New” Prostate Cancer InfoLink thanks the following specialists in the diagnosis and management of prostate cancer for agreeing to participate as members of our Scientific Advisory Board. They receive no remuneration for this kindness.
Judd W. Moul, MD, FACS (Chairman) — Dr. Moul is professor and chief, Division of Urologic Surgery, and director of the Duke Prostate Center, Duke University Health System, Durham, North Carolina. He is an internationally respected member of the urologic oncology community and was the founding director of the Center for Prostate Disease Research at the Uniformed Services University of the Health Sciences in Rockville, MD and at Walter Reed Army Medical Center in Washington, DC. For additional information about Dr. Moul, please click here.
Georg Bartsch, MD — Dr. Bartsch is professor and chairman, Department of Urology, University of Innsbruck, Innsbruck, Austria. For the past 20 years, Dr. Bartsch has overseen the Tyrol Prostate Cancer Demonstration Project, a major initiative to explore the consequences of early detection and treatment of prostate cancer in the Tyrol, a federal state of Austria, and to examine the impact of this initiative on mortality in the Tyrol compared to prostate cancer mortality in other parts of Austria. For additional information about Dr. Bartsch (in English), please click here.
Timothy B. Boone, MD, PhD — Dr. Boone is Chairman of the Urology Department and medical director of the Urodynamic Laboratory at the The Methodist Hospital System, Houston, Texas. He specializes in issues related to urinary incontinence, specifically including incontinence consequent to radical prostatectomy. For additional information about Dr. Boone, please click here.
David G. Bostwick, MD, MBA — Dr. Bostwick is CEO and medical director of Bostwick Laboratories, Inc., one of the world’s most repected commercial pathology laboratories, exclusively focused on diagnosis of cancer of urologic organs (prostate, urinary bladder, kidney, and testis) and with a special interest in prostate cancer. He was formerly a professor of pathology and urology at the Mayo Clinic, which he left to found Bostwick Laboratories. He is also a past president of the International Society of Urological Pathology. For additional information about Dr. Bostwick, please click here.
Michael Burke, MD — Dr. Burke is clinical director of psychiatric oncology at the Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia. For 15 years he has provided care for and education about the psychological and social issues that often accompany prostate cancer patients and families. His research has also been focused on quality of life issues in men with prostate cancer. He was a founding member of the VA Interdisciplinary Prostate Cancer Clinic in Miami, Florida (one of the first such clinics in the world). For additional information about Dr. Burke, please click here.
Arthur L. Burnett, II, MD — Dr. Burnett is professor, Department of Urology, at Johns Hopkins University School of Medicine, where he is also Director of the Basic Science Laboratory in Neuro-urology. He is recognized as a world authority in the science and medicine of male erectile dysfunction. Currently, Dr. Burnett holds professional appointments at the Johns Hopkins Hospital, including Director of the Male Consultation Clinic and clinician-scientist at the James Buchanan Brady Urological Institute. For more information about Dr. Burnett, please click here.
Barrie R. Cassileth, MS, PhD — Dr. Cassileth holds the Laurance S. Rockefeller Chair in Integrative Medicine and is chief of the Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York. She has worked in alternative and complementary (integrative) medicine and psychosocial aspects of cancer care for over 25 years. She joined MSKCC in 1999 to create the Integrative Medicine Service, a program that offers inpatient therapies at Memorial Hospital and outpatient services at the Bendheim Integrative Medicine Center. For additional information about Dr. Cassileth, please click here.
Philip Kantoff, MD — Dr. Kantoff is one of the world’s pre-eminent authorities on advanced prostate cancer. He is a professor of medicine at Harvard Medical School and director of the Lank Center for Genitourinary Oncology in the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. He is also the leader of the Dana-Farber/Harvard Cancer Center Prostate Cancer Program; director of the prostate cancer Specialized Program of Research Excellence (SPORE); and chief clinical research officer and chief of the Division of Solid Tumor Oncology at Dana-Farber. For additional information about Dr. Kantoff, please click here.
Mark S. Litwin, MD, MPH — Dr. Litwin is Professor of Urology and Health Services, Department of Urology, UCLA Healthcare and Department of Health Services, UCLA School of Public Health, University of California Los Angeles, Los Angeles, California. His practice is limited to urologic oncology focused on prostate, bladder, testis, kidney, and penile cancer. He studies health-related quality of life in men with prostate cancer, medical outcomes in urologic oncology, quality of care in urology, and the epidemiologic burden of urologic diseases in America. One of his long-time research interests has been the quality of men’s lives after treatment for early and late stage prostate cancer. He created and directs IMPACT, a public assistance program for low-income, uninsured California men with prostate cancer. For additional information about Dr. Litwin, please click here.
Heather Payne, MB BS, MRCP, FRCR — Dr. Payne is a Consultant in Clinical Oncology at University College London Hospitals and at The Institute of Urology, London, England. Working within a multidisciplinary team, she is the lead in treatments for prostate cancer with radiotherapy, hormone therapy, and novel therapies, and she has pioneered a program of high dose rate brachytherapy. Her research interests, include hormone therapy, radiotherapy, chemotherapy, and quality of life and decision making for men with prostate cancer. For additional information about Dr. Payne, please click here.
Howard M. Sandler, MD — Dr. Sandler is Newman Family Professor and Senior Associate Chair, Department of Radiation Oncology and Professor, Department of Urology, University of Michigan Health System. He has particular interests in dose escalation and novel techniques for prostate irradiation. He is also actively involved in prostate cancer clinical trial implementation through the Radiation Therapy Oncology Group (RTOG). For more information about Dr. Sandler, please click here.
J. Brantley Thrasher, MD, FACS — Dr. Thrasher is Professor and William L. Valk Chair of Urology and Co-Director of the Operative Services at the University of Kansas Medical Center in Kansas City, Kansas. He is involved in basic science and in clinical research in the development of new diagnostic techniques and treatments for prostate, bladder and kidney cancer. His many editorial appointments include membership of the Editorial Advisory Board of American Family Physician (a journal with one of the largest circulations of any medical journal). For more information about Dr. Thrasher, please click here.
